Concepedia

Publication | Open Access

Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme

DOIFull Paper Access

330

Citations

67

References

2005

Year

David A. Reardon, Merrill J. Egorin, Jennifer A. Quinn, Jeremy N. Rich, Idharan Gururangan, James J. Vredenburgh, Annick Desjardins, Sith Sathornsumetee, James M. Provenzale, James E. Herndon,
Journal of Clinical Oncology

Abstract

Imatinib mesylate plus hydroxyurea is well tolerated and associated with durable antitumor activity in some patients with recurrent GBM.

References

YearCitations

Page 1